SCHEMBL14883241

SCHEMBL14883241

Cc1cccc(-n2nccn2)c1C(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 9/20 0.34
HCRTR2 O43614 8/20 0.34
KCNH2 Q12809 2/20 0.34
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
FLT3 P36888 1/20 0.32
GSK3B P49841 1/20 0.32
SCN4A P35499 3/20 0.31
MAOA P21397 3/20 0.31
MAOB P27338 2/20 0.31
LMNA P02545 2/20 0.31
SCN1A P35498 2/20 0.31
SCN5A Q14524 2/20 0.31
SCN9A Q15858 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14883121 0.80 HCRTR1 (0.38) HCRTR1HCRTR2
SCHEMBL14850900 0.76 ADRB1 (0.44) HCRTR1HCRTR2KCNH2LMNATSHR
SCHEMBL4550926 0.76 FLT3 (0.44) FLT3GSK3BLMNATSHRMEN1
SCHEMBL19732402 0.74 GABRA1 (0.38) HCRTR1HCRTR2CA1CA2LMNA
SCHEMBL16787393 0.73 HCAR1 (0.38) HCRTR1HCRTR2KCNH2FLT3GSK3B
SCHEMBL17947808 0.73 LMNA (0.41) HCRTR1HCRTR2KCNH2LMNATSHR
SCHEMBL598366 0.72 CA1 (0.50) KCNH2CA1CA2CA7CA9
SCHEMBL12862574 0.71 FAAH (0.48) HCRTR1HCRTR2CA1CA2LMNA
SCHEMBL21375830 0.70 HCRTR1 (0.38) HCRTR1HCRTR2KCNH2SCN4AMAOA
SCHEMBL19229967 0.70 HCRTR1 (0.36) HCRTR1HCRTR2KCNH2FLT3GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9156819-B2 2-pyridyloxy-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2015-10-13 US disclosed
US-9156819-B2 2-pyridyloxy-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2015-10-13 US disclosed
US-20130102619-A1 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2013-04-25 US disclosed
US-20130102619-A1 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2013-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102619-A1 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NTSR2 HCRTR1 2/4885HCRTR2 1/4885KCNH2 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.